Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Anti-Rheumatics Market Size Worth Around US$ 72 Bn by 2027

Acumen Research and Consulting, Recently Published Report on "Anti-Rheumatics Market Size, Share, Growth, Trends, Company Revenue, Production and Forecast, 2020 - 2027"

Acumen Research and Consulting Logo

News provided by

Acumen Research and Consulting

Jul 07, 2020, 10:30 ET

Share this article

Share toX

Share this article

Share toX

LOS ANGELES, July 7, 2020 /PRNewswire/ -- The anti-rheumatics market size is expected to be worth around US$ 72 bn by 2027 and growing at a CAGR of 3% over the forecast period 2020 – 2027.

The development of warm, swollen and painful joints in rheumatoid arthritis is a medical condition which primarily affects a person's hands and wrists. The use of various medications known as anti-rheumatic medicines is the treatment of this disease. Moreover, these medicines are also used to modify the medical condition's course. For instance, disease-modifying anti-rheumatic medicines are anti-rheumatic medicines which slow the development of the disease. Drugs like anti-inflammatory and anti-steroid drugs are also being used in rheumatoid arthritis diagnosis.

Get Free Report Sample Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1972

Asia-Pacific is Witnessing High Growth and is Expected to Follow the Same Trend Over the Forecast Period

Asia Pacific is expected to propel the growth of global anti-rheumatics market and is likely to continue its dominance during forecast period due to rising healthcare expenditure in the region. Moreover, China and India's low manufacturing cost has led to a rise in production plants that draw pharmaceutical and biotechnological companies from around the world to the Asia-Pacific. The rheumatoid arthritis disease prevalence increases are expected to fuel the region demand during the forecast period. For instance, the number of rheumatoid Arthritis cases has risen from 183,272 in 2007 to 263,365 in 2017 only in India, as per the Institute for Health Metrics and Evaluation. Analyzing the number of cases in other major Asia-Pacific countries will require a large and consistent contribution from everyone for the care of rheumatoid arthritis.

Market dynamics

Increasing geriatric population is the key factor that drives the growth of global anti-rheumatics market. The total population is projected to hit 9.3 billion in 2050, according to the Global Population Prospects of the United Nations, and about 21% of the population is predicted to be 60 and older. In addition to the ageing and growing population, the development of the global anti-rheumatic market is driving due to increased buying capacity and access to affordable medical and prescription services for small and medium-sized families. The concentration of pharmaceutical companies on the demand for rare and specialist diseases are other factors that contribute to this development. Advanced biological advances, nucleic acid therapies and cell therapies have generated developments in the market that drive this development.

View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/anti-rheumatics-market

On the other hand, high cost and stringent regulations are projected to impact global anti-rheumatics industries growth opportunities in key markets. Anti-Rheumatic firms are forced to reduce R&D spending due to slowdown of growth in recent years and thus the global anti-rheumatic market is anticipated to hinder development as new product revenues are a major part of the pharmaceutical company's revenue owing to the exclusive use of medicines.. Generic producers' pricing is still a challenge for big brands. For instance, In 2013, Cipla released the Etacept Biosimilar of Ethanercept for treating rheumatic diseases, which is the cheaper alternative to the Enbrel brand of Amgen and Pfizer.

The global anti-rheumatics market includes prominent players such as Johnson & Johnson, Pfizer, Inc., Bristol-Myers Squibb Company, Celegene Corporations, F. Hoffmann-La Roche Ltd., MedImmune, LLC, Biogen Inc., Celltrion Inc., Takeda Pharmaceutical Company Ltd., Amgen Inc. and others.

  • Browse more Healthcare and Pharmaceuticals Industry Research Report@ https://www.acumenresearchandconsulting.com/industry-categories/healthcare-and-pharmaceuticals

Recent Developments

  • In October 2019, The World Arthritis Day, a global awareness day designed to raise awareness of the signs of rheumatic and musculoskeletal disorders (RMDs), has been recognized by the European League against Rheuma (EULar).
  • In December 2019, Bristol-Myers Squibb announces U.S. FDA breakthrough therapy designation for ORENCIA® (abatacept) a possible lifetime risk following stem cell transplantation, to help avoid acute graft- or host illness advanced data systems (ADS)
  • In June 2019, biogen to present new safety and efficacy data on biosimilars and estimates 1.8 billion euros in savings for the European healthcare system in 2019

Key Target Audience

  • Research and Development (R&D) Companies
  • Seropositive Rheumatoid Arthritis Drug Suppliers
  • Academic Medical Institutes and Universities
  • Seropositive Rheumatoid Arthritis Drug Manufacturers
  • Medical Research Laboratories

Market Segmentation

Market By Drug Class

  • Disease Modifying Anti-rheumatics Drugs (DMARD'S)
  • Nonsteroidal Anti-inflammatory Drugs (NSAID'S)
  • Corticosteroids
  • Uric Acid Drugs
  • Others

Market By Type

  • Prescription-based Drugs
  • Over-the-counter Drugs

Market By Distribution Channel

  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies

Market By End-User

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Healthcare Specialty Process

Anti-Rheumatics Market By Geography

North America

  • U.S.
  • Canada

Europe

  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe

Asia-Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC
  • South Africa
  • Rest of Middle East & Africa

Request for Customization@ https://www.acumenresearchandconsulting.com/request-customization/1972

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report@ https://www.acumenresearchandconsulting.com/buy-now/0/1972

If you would like to place an order or have any questions, please feel free to contact at [email protected] | +1-407-915-4157 OR +1-408-900-9135

About Us

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. Among the industries served include aerospace and defense, information and communication technology (ICT), semiconductor and electronics, healthcare and pharmaceuticals, chemicals, advanced materials, banking, finance services and insurance (BFSI), and others.

Our collective industry experience of over 100 years has helped us to offer appropriate market information and our global reach and regional connects ensures appropriate insights into regional markets to guarantee apt delivery of information.

Our regional market intelligence helps our clients to identify potential opportunities and develop growth strategies across regions and countries. Our services are geared towards offering best market research to our clients.

Contact Us:
Mr. Frank Wilson
Acumen Research and Consulting
17890, Castleton St #218, Rowland Heights, CA 91748 United States
Tel: +1-407-915-4157 OR +1-408-900-9135
Email: [email protected] 
Website: https://www.acumenresearchandconsulting.com

SOURCE Acumen Research and Consulting

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.